Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Ventyx

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema. The company’s chief business officer

MarketBeat

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

MarketBeat

Ventyx Stock Is Rallying Thursday: What's Driving The Surge?

Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232 in patients with obesity and cardiovascular risk factors.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Ventyx (VTYX) Shares Soared 86.5% After Hours?

Ventyx Biosciences Inc. (NASDAQ:VTYX) jumped 86.53% to $7.20 in after-hours trading on Wednesday after the company reported positive Phase 2 trial results for its obesity and cardiovascular risk drug candidate, VTX3232.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Organisations

US Food and Drug Administration

63 stories

Nature Medicine

36 stories

Medicines and Healthcare products Regulatory Agency

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United Kingdom

144,352 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.